Carnegie Investment Counsel’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,384
| Closed | -$220K | – | 469 |
|
|
2024
Q3 | $220K | Hold |
5,384
| – | – | 0.01% | 439 |
|
|
2024
Q2 | $207K | Hold |
5,384
| – | – | 0.01% | 452 |
|
|
2024
Q1 | $231K | Sell |
5,384
-35
| -0.6% | -$1.44K | 0.01% | 455 |
|
|
2023
Q4 | $201K | Buy |
+5,419
| New | +$195K | 0.01% | 472 |
|
|
2023
Q1 | – | Sell |
-6,137
| Closed | -$216K | – | 513 |
|
|
2022
Q4 | $216K | Buy |
+6,137
| New | +$204K | 0.01% | 480 |
|
|
2021
Q3 | – | Sell |
-6,369
| Closed | -$317K | – | 476 |
|
|
2021
Q2 | $317K | Sell |
6,369
-444
| -7% | -$21.3K | 0.01% | 384 |
|
|
2021
Q1 | $305K | Buy |
6,813
+106
| +2% | +$4.81K | 0.01% | 375 |
|
|
2020
Q4 | $309K | Buy |
6,707
+560
| +9% | +$25.7K | 0.01% | 358 |
|
|
2020
Q3 | $289K | Hold |
6,147
| – | – | 0.01% | 347 |
|
|
2020
Q2 | $313K | Hold |
6,147
| – | – | 0.02% | 339 |
|
|
2020
Q1 | $291K | Hold |
6,147
| – | – | 0.02% | 327 |
|
|
2019
Q4 | $361K | Buy |
6,147
+824
| +15% | +$45.8K | 0.02% | 339 |
|
|
2019
Q3 | $284K | Sell |
5,323
-2,186
| -29% | -$112K | 0.02% | 352 |
|
|
2019
Q2 | $376K | Hold |
7,509
| – | – | 0.02% | 343 |
|
|
2019
Q1 | $392K | Buy |
7,509
+1,158
| +18% | +$57.9K | 0.03% | 329 |
|
|
2018
Q4 | $303K | Buy |
+6,351
| New | +$313K | 0.03% | 312 |
|
|
2018
Q3 | – | Sell |
-6,043
| Closed | -$301K | – | 357 |
|
|
2018
Q2 | $301K | Hold |
6,043
| – | – | 0.02% | 318 |
|
|
2018
Q1 | $302K | Sell |
6,043
-2,000
| -25% | -$93.1K | 0.03% | 309 |
|
|
2017
Q4 | $362K | Sell |
8,043
-63,463
| -89% | -$2.93M | 0.03% | 301 |
|
|
2017
Q3 | $3.63M | Sell |
71,506
-39,070
| -35% | -$1.98M | 0.42% | 71 |
|
|
2017
Q2 | $5.63M | Sell |
110,576
-7,846
| -7% | -$418K | 0.69% | 44 |
|
|
2017
Q1 | $6.26M | Buy |
118,422
+17,386
| +17% | +$882K | 0.78% | 37 |
|
|
2016
Q4 | $5.02M | Sell |
101,036
-19,404
| -16% | -$959K | 0.67% | 51 |
|
|
2016
Q3 | $6.2M | Buy |
120,440
+60,194
| +100% | +$3.3M | 0.89% | 35 |
|
|
2016
Q2 | $3.4M | Buy |
60,246
+33,569
| +126% | +$1.77M | 0.48% | 64 |
|
|
2016
Q1 | $1.35M | Sell |
26,677
-72
| -0.3% | -$3.59K | 0.21% | 126 |
|
|
2015
Q4 | $1.38M | Buy |
26,749
+1,392
| +5% | +$71K | 0.24% | 108 |
|
|
2015
Q3 | $1.32M | Sell |
25,357
-2,485
| -9% | -$129K | 0.23% | 109 |
|
|
2015
Q2 | $1.45M | Buy |
27,842
+4,542
| +19% | +$256K | 0.25% | 98 |
|
|
2015
Q1 | $1.4M | Buy |
23,300
+3,691
| +19% | +$212K | 0.24% | 101 |
|
|
2014
Q4 | $1.06M | Sell |
19,609
-993
| -5% | -$55.6K | 0.2% | 119 |
|
|
2014
Q3 | $1.18M | Buy |
20,602
+17,106
| +489% | +$1.05M | 0.24% | 114 |
|
|
2014
Q2 | $234K | Sell |
3,496
-320
| -8% | -$21.7K | 0.05% | 210 |
|
|
2014
Q1 | $255K | Hold |
3,816
| – | – | 0.07% | 190 |
|
|
2013
Q4 | $255K | Hold |
3,816
| – | – | 0.07% | 190 |
|
|
2013
Q3 | $239K | Hold |
3,816
| – | – | 0.07% | 190 |
|
|
2013
Q2 | $238K | Buy |
+3,816
| New | +$242K | 0.08% | 178 |
|
Other funds holding GSK
JEST
Carnegie Investment Counsel's GSK Position: Q4 2024 in Review
Carnegie Investment Counsel sold out of GSK (GSK) in Q4 2024, closing a stake of 5,384 shares — an estimated $220K sold.
Carnegie Investment Counsel first reported a position in GSK in Q2 2013 and held it in 37 quarters. The position peaked at $6.26M in Q1 2017. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.
- Carnegie Investment Counsel reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
- Carnegie Investment Counsel sold 5,384 GSK shares in Q4 2024, an estimated $220K.
- Carnegie Investment Counsel first reported a position in GSK in Q2 2013 and held it in 37 quarters.
- Carnegie Investment Counsel's GSK position peaked at $6.26M in Q1 2017.
- 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.
Based on Carnegie Investment Counsel's 13F filing for Q4 2024, filed 15 Jan 2025.